Background The potential benefits and risks of the use of dual antiplatelet therapy beyond a
12-month period in patients receiving drug-eluting stents have not been clearly established …

Background—The risks and benefits of long-term dual antiplatelet therapy remain unclear.
Methods and Results—This prospective, multicenter, open-label, randomized comparison …

Background Dual antiplatelet therapy is recommended after coronary stenting to prevent
thrombotic complications, yet the benefits and risks of treatment beyond 1 year are …

Background—The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for
long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We …

Background: The currently recommended duration of dual antiplatelet therapy (DAPT) in
drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis …

Background—The optimal duration of dual antiplatelet therapy (DAPT) after implantation of
drug-eluting coronary stents remains undetermined. We aimed to test whether 6-month …

BACKGROUND: Concern regarding the rate of delayed acute stent thrombosis associated
with drug-eluting stent (DES) treatment has resulted in upward revision of the advised …

Current guidelines recommend 12 months of dual antiplatelet therapy (DAPT) after drug-
eluting stent (DES) implantation in the absence of increased bleeding risk. Studies have …

The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated
in randomized studies with apparently conflicting results. Although longer exposure …

Objectives The aim of this study was to determine whether 1 month of dual-antiplatelet
therapy (DAPT) followed by aspirin monotherapy after polymer-free drug-coated stent (PF …